No Data
No Data
Chengdu Easton Biopharma Gets Nod to Register Compound Glycyrrhizin Tablets
Chengdu Easton Biopharmaceuticals (688513.SH): Compound Glycyrrhizin Tablets Obtains Pharmaceutical Registration Certificate.
Chengdu Easton Biopharmaceuticals (688513.SH) announced that the company has recently received approval from the National Medical Products Administration for...
Chengdu Easton Biopharmaceuticals (688513.SH): has repurchased 1.8788% of the company's shares.
Chengdu Easton Biopharmaceuticals (688513.SH) announced on August 2nd that as of the end of July 2024, the company had repurchased a total of 3,316,769 shares through centralized bidding transactions, accounting for 1.8788% of the current total share capital. The highest purchase price was 56.05 yuan/share and the lowest was 28.12 yuan/share, with a total transaction amount of RMB 123,694,177.73 (excluding stamp duty, transaction commission and other trading costs).
Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) Market Cap Increased by CN¥513m, Insiders Receive a 49% Cut
Chengdu Easton Biopharmaceuticals' Ubenimex Capsules Passes Regulatory Evaluation
Chengdu Easton Biopharmaceuticals (688513.SH): Ubenimex Capsules Pass Generic Drug Quality and Efficacy Consistency Evaluation.
Chengdu Easton Biopharmaceuticals (688513.SH) announced on July 18th that it has received the approval notification for the supplementary drug application of the chemical drug Ubenimex capsules issued by the National Medical Products Administration. The main ingredient of Ubenimex capsules is Ubenimex, which is indicated for enhancing immune function and can be used as an adjuvant treatment for cancer chemotherapy, radiotherapy, immunodeficiency in the elderly, etc. It can be used in combination with chemotherapy, radiotherapy, and hematopoietic stem cell transplantation for patients with leukemia, multiple myeloma, myelodysplastic syndrome, solid tumors, and other diseases.
No Data